Last updated: July 29, 2026
Galderma Laboratories, L.P. sued Amneal Pharmaceuticals, LLC in the Eastern District of Texas in 2019 (case no. 1:19-cv-00440). The case name indicates a patent infringement dispute tied to Galderma’s dermatology product and Amneal’s proposed generic, with the parties litigating one or more Orange Book-listed patents and associated infringement and validity theories. A complete, claim-level litigation summary (asserted patent numbers, claim construction results, trial/settlement posture, injunction terms, and final judgments) cannot be produced from the information provided.
What patents were asserted in Galderma v. Amneal (1:19-cv-00440)?
Answer: Not identifiable from the provided input.
Which Orange Book patents were at issue?
No asserted Orange Book patent numbers, listed products, or expiration dates are included in the provided information, so the specific Orange Book listings tied to the infringement allegations cannot be determined.
Which claims of the asserted patents were targeted?
No complaint-level claim references, infringement contentions, or “for which claims” mappings are provided.
What is the case timeline for 1:19-cv-00440 (filings, motions, Markman, outcome)?
Answer: Not identifiable from the provided input.
Key docket milestones that drive exclusivity and launch risk
No filing dates, amendment dates, Paragraph IV notices, or docket events (Markman, summary judgment, Daubert, trial, post-trial, appeal, or dismissal) are provided.
How did Galderma frame infringement in the complaint?
Answer: Not identifiable from the provided input.
Does the infringement theory involve formulations, methods of use, or combination products?
The product, dosage form, and the asserted patent types (composition, formulation, method-of-use, or manufacturing method) are not specified.
How did Amneal respond (validity defenses, non-infringement, unenforceability)?
Answer: Not identifiable from the provided input.
What validity arguments were raised (obviousness, anticipation, indefiniteness, written description, enablement)?
No asserted references, PTAB proceedings, or invalidity grounds are provided.
Were there inequitable conduct or prosecution history estoppel defenses?
No inequitable conduct allegations or prosecution history estoppel positions are included.
What was the court’s claim-construction (Markman) ruling and why does it matter?
Answer: Not identifiable from the provided input.
How did construction narrow or broaden patent scope
No claim construction orders or adopted constructions are provided, so the impact on infringement and validity cannot be analyzed.
What dispositive motions were decided (summary judgment, injunction standards, stay)?
Answer: Not identifiable from the provided input.
Did the court grant or deny preliminary injunction or enter a Section 283 stay?
No injunction or stay details are provided.
Did the parties reach a settlement, and what did it include (timing, carve-outs, license terms)?
Answer: Not identifiable from the provided input.
What launch date restrictions likely applied after settlement
No settlement agreement terms are provided.
What does this case mean for generic entry risk for Amneal products?
Answer: Not identifiable from the provided input.
How Paragraph IV exposure translates into launch timing
Without the specific Orange Book patents and their expiration and any settlement terms, launch-risk modeling cannot be performed.
How does Galderma’s patent estate strength compare with other dermatology competitors?
Answer: Not identifiable from the provided input.
Competitive posture by molecule and formulation platform
No drug identity, patent families, or competitor list is provided.
What is the FDA regulatory status tied to the litigation (ANDA/505(b)(2), application number, approval dates)?
Answer: Not identifiable from the provided input.
Orange Book listing status (listed, withdrawn, expired)
No Orange Book status data is provided.
Jurisdiction and procedural posture: why Eastern District of Texas matters here
Answer: Not identifiable from the provided input.
Venue, transfer, and appeal
No transfer or appeal information is provided.
Key Takeaways
Answer: A litigation summary and analysis cannot be completed from the supplied details alone because the record content required for an infringement, validity, and outcome review is not present (asserted patents, docket events, court orders, and final disposition).
FAQs
- What patents were asserted in Galderma Laboratories v. Amneal Pharmaceuticals (1:19-cv-00440)?
- Did the court issue a Markman order in 1:19-cv-00440, and what constructions were adopted?
- Was there a settlement in Galderma v. Amneal, and did it include launch restrictions?
- What FDA application (ANDA or 505(b)(2)) and Orange Book patents were tied to the dispute?
- How would the decision affect generic launch timing for the product at issue?
References (APA)
No sources were provided in the prompt to cite.
